Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Open Access
- 12 August 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer
- Vol. 27 (1), 122-128
- https://doi.org/10.1007/s12282-019-01001-1
Abstract
Purpose To explore the actual status of chemotherapy-induced nausea and vomiting (CINV) through a multicenter prospective cohort study. Methods Patients with breast cancer treated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy were eligible. A 7-day diary was provided for all patients. Acute and delayed CINV were defined as nausea and vomiting that developed ≤ 24 or > 24 h after the start of chemotherapy, respectively. The severity of nausea was evaluated with a visual analog scale (VAS). We also assessed the accuracy of estimations of CINV by medical staff. Results In total, 426 patients were included; 352 patients (82.6%) received HEC, and 74 (17.3%) received MEC. In the acute phase, 44.9% of patients receiving HEC and 5.4% receiving MEC experienced nausea, and 12.8% receiving HEC and none receiving MEC experienced vomiting. More patients experienced nausea in both groups and vomiting in MEC during the delayed phase (nausea: 59.4% in HEC and 44.6% in MEC group; vomiting: 11.1% in HEC; and 13.5% in MEC group) than during the acute phase. Estimations of CINV by medical staff were not accurate, with a kappa coefficient of 0.10 and 0.08 for acute nausea and vomiting and 0.02 and 0.01 for delayed. The VAS scores showed that in the HEC group, the degree of nausea was worst on the first day. Conclusions The degree of nausea was worst in the acute phase, although delayed nausea was more in proportion in HEC. Estimation by medical staff is not accurate.Funding Information
- research grant from the Public Health Research Foundation
This publication has 11 references indexed in Scilit:
- Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summaryInternational Journal of Clinical Oncology, 2015
- Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of JapanInternational Journal of Clinical Oncology, 2015
- Residential racial segregation and mortality among black, white, and Hispanic urban breast cancer patients in Texas, 1995 to 2009Cancer, 2015
- Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE StudyJournal of Oncology Practice, 2014
- The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Annals of Oncology, 2012
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials UnitAnnals of Oncology, 2009
- Incidence of chemotherapy‐induced nausea and emesis after modern antiemeticsCancer, 2004
- Is breast cancer survival improving?Cancer, 2003